We selected this administration paradigm for our initial experiment because it effectively inhibited phosphorylation of whole brain c-Jun N-terminal kinase (JNK), a kinase downstream of MLK3, in an in vivo model of HAND [18]. The gene discussed is MAP3K11; the disease is HIV-associated neurocognitive disorder.